GlassScriptPhysician profile
Louis M Benevento
NPI 1063445666
$2,445.68
in general payments reported to CMS, 2019-2025
24 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $133 · 2021: $488 · 2022: $444 · 2023: $613 · 2024: $340 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $397.17 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.45 | 2019-2023 | Spiriva Respimat |
| Novo Nordisk INC | $356.38 | 2019-2025 | Ozempic |
| Insulet Corporation | $308.55 | 2021-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $229.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $176.78 | 2022-2024 | Trelegy Ellipta, Arexvy, Pediarix |
| Abbvie INC. | $93.80 | 2022-2024 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $72.18 | 2021-2024 | Airsupra, Farxiga |
| Mylan Specialty L.P. | $58.53 | 2022-2024 | Yupelri |
| Abbott Laboratories | $45.23 | 2023-2024 | Freestyle Libre 3 |
| Medtronic Minimed, INC. | $45.02 | 2019-2020 | |
| Amgen INC. | $37.74 | 2021-2024 | Evenity, Prolia |
| Medtronic, INC. | $30.97 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Recordati_rare_diseases_inc. | $30.73 | 2025 | Isturisa |
| Tactile Systems Technology INC | $28.84 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $25.74 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $23.76 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.88 | 2024 | Jynarque |
| Beta Bionics, INC. | $17.38 | 2024 | Ilet Bionic Pancreas |
| Becton, Dickinson and Company | $15.94 | 2023 | Bd Onclarity |
| Xeris Pharmaceuticals, INC. | $15.59 | 2022 | |
| Pfizer INC. | $14.23 | 2019 | |
| Merck Sharp & Dohme LLC | $13.33 | 2022 | |
| Esperion Therapeutics, INC. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Benevento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.